Northern Trust’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $14.7M | Buy |
2,914,872
+519,684
| +22% | +$2.63M | ﹤0.01% | 1835 |
|
|
2025
Q1 | $12.7M | Buy |
2,395,188
+677
| +0% | +$3.58K | ﹤0.01% | 1901 |
|
|
2024
Q4 | $16.2M | Buy |
2,394,511
+371,886
| +18% | +$2.51M | ﹤0.01% | 1833 |
|
|
2024
Q3 | $13.3M | Buy |
2,022,625
+708,015
| +54% | +$4.67M | ﹤0.01% | 1895 |
|
|
2024
Q2 | $9.86M | Buy |
1,314,610
+27,920
| +2% | +$209K | ﹤0.01% | 2006 |
|
|
2024
Q1 | $12.8M | Sell |
1,286,690
-8,897
| -0.7% | -$88.7K | ﹤0.01% | 1893 |
|
|
2023
Q4 | $12.8M | Sell |
1,295,587
-13,345
| -1% | -$132K | ﹤0.01% | 1904 |
|
|
2023
Q3 | $10M | Buy |
1,308,932
+56,945
| +5% | +$436K | ﹤0.01% | 2002 |
|
|
2023
Q2 | $9.35M | Buy |
1,251,987
+96,210
| +8% | +$719K | ﹤0.01% | 2112 |
|
|
2023
Q1 | $7.71M | Sell |
1,155,777
-3,926
| -0.3% | -$26.2K | ﹤0.01% | 2195 |
|
|
2022
Q4 | $8.94M | Buy |
1,159,703
+26,005
| +2% | +$200K | ﹤0.01% | 2080 |
|
|
2022
Q3 | $12.1M | Buy |
1,133,698
+152,416
| +16% | +$1.62M | ﹤0.01% | 1853 |
|
|
2022
Q2 | $7.99M | Buy |
981,282
+121,738
| +14% | +$991K | ﹤0.01% | 2199 |
|
|
2022
Q1 | $6.15M | Sell |
859,544
-26,417
| -3% | -$189K | ﹤0.01% | 2459 |
|
|
2021
Q4 | $15.2M | Buy |
885,961
+635,290
| +253% | +$10.9M | ﹤0.01% | 1962 |
|
|
2021
Q3 | $5.77M | Buy |
250,671
+8,295
| +3% | +$191K | ﹤0.01% | 2636 |
|
|
2021
Q2 | $8.85M | Buy |
+242,376
| New | +$8.85M | ﹤0.01% | 2457 |
|